In preclinical studies, Nrg4 as a novel endocrine checkpoint exerted protective effects against various metabolic diseases such as IR, obesity, NAFLD, and diabetes; while discrepancies were noted in clinical investigations, more well-designed studies with large samples are needed in the future to address the heterogeneity and inconsistency. This evidence concerns the gene NRG4 and metabolic dysfunction-associated steatotic liver disease.